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Branchio-oto-renal (BOR) syndrome is an autosomal dominant disorder
characterized by the associations of hearing loss, branchial arch defects
and renal anomalies. Branchiootic (BO) syndrome is a related disorder
that presents without the highly variable characteristic renal anomalies of
BOR syndrome. Dominant mutations in the human homologue of the
Drosophila eyes absent gene (EYA1) are frequently the cause of both
BOR and BO syndromes. We report a South African family of Afrikaner
descent with affected individuals presenting with pre-auricular
abnormalities and either hearing loss or bilateral absence of the kidneys.
Genetic analysis of the pedigree detected a novel EYA1 heterozygous
nonsense mutation in affected family members but not in unaffected
family members or a random DNA panel. Through mutational analysis,
we conclude that this particular mutation is the cause of BOR/BO
syndrome in this family as a result of a truncation of the EYA1 protein
that ablates the critical EYA homologous region. To the best of our
knowledge, this is the first case of BOR/BO syndrome reported in Africa
or in those of the Afrikaner descent.
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Branchio-oto-renal (BOR) syndrome (OMIM
113650) is an autosomal dominant developmen-
tal disorder of the kidney and urinary tract,
accompanied with hearing loss (1) and presenting
with a wide intrafamilial variability and variable
penetrance (2). Branchiootic (BO) syndrome
(OMIM 602588) is a related disorder that
presents without the highly variable renal anom-
alies of BOR syndrome. However, it has been
demonstrated that allelic variants of EYA1
mutations can be the cause of both BOR and
BO syndromes (3–6). It is estimated that BOR/
BO syndrome occurs at a frequency of 1:40,000
live births and affects approximately 2% of
profoundly deaf children (7).
EYA1 (NM_172060) (8q13.3) functions as a
transcription cofactor in the conserved EYA-SIX-
PAX developmental network (8). In mammals,
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EYA1-mediated gene regulation is critical to the
proper formation of many organ systems and
tissues (4, 9–12) and is one of the earliest known
markers of the metanephric mesenchyme (13).
The EYA1 protein does not contain a known
DNA-binding domain but does contain a highly
conserved EYA homologous region (EYAhr),
which is encoded by exons 9–16 of the gene
(Fig. 1a). The EYAhr is necessary for the protein
to bind with its respective binding partners, such
as SIX1, in order to form transcription com-
plexes and regulate transcription properly (9, 12,
14, 15). In humans, more than 50 mutations in
the EYA1 gene have been associated with BOR/
BO syndromes (16), all of which seem to either
impair the function of the EYAhr or ablate the
region altogether.
We report the identification of a novel nonsense
mutation as well as a novel single nucleotide
polymorphism (SNP) within the EYA1 gene, as
found in a South African Afrikaner kindred. To
the best of our knowledge, this is the first
reported case of BOR/BO syndrome in Africa
or in individuals of Afrikaner descent.
Materials and methods
Informed consent was obtained from all partic-
ipants before enrolling into the study (University
of Michigan IRBMED # 2004-0322). Informed
consent documents were downloaded from our
research group’s Web site at www.kidneygenes.
com by the family’s physician.
EYA1 exons were amplified by PCR using
methods previously reported by Abdelhak et al.
(3). Heterozygous mutations were screened
against a random panel of healthy controls
utilizing capillary heteroduplex analysis as
described by Hoskins et al. (17).
Maximum entropy (MaxENT) scores were
determined to assess the strengths of the 5# and
3# splice sites (ss) of introns 7 and 15 of EYA1




Family JCA7 is of Afrikaner descent and was
identified during pre-natal ultrasound screening
where the proband (III.3) was diagnosed as
having oligohydramnios and bilateral renal
agenesis/Potter’s sequence. The family’s medical
review indicated a history of bilateral renal
agenesis/Potter sequence in a previous pregnancy
(III.1, unavailable for analysis). In addition, it
was found that the father of the proband (II.3)
had a unilateral pre-auricular pit (Fig. 2a) with an
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Fig. 1. (a) Schematic of the 156 kb EYA1 gene. Alternative first exons are denoted by the gray boxes and the black boxes
denote exons 2–16. The EYA homologous region is encoded by exons 9–16. (b) Schematic of exons 7 and 8 with the introns
removed. (c) In-frame partial sequences of exons 7 and 8 following splicing of intron 7 and position of the 727G.T
transversion (circled) identified in family members II.3 and III.3. This transversion would result in a stop codon instead of
glutamic acid at position 243. Analysis of the pedigree also revealed a novel single nucleotide polymorphism, IVS15-3 C.T, in
intron 15 adjacent to the exon 16 acceptor site (arrow).
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ipsilateral overfolded superior helix and hearing
loss of an unknown etiology. Pre-auricular pits
and hearing loss are present in 82% and 93% of
individuals diagnosed with BOR/BO syndrome,
respectively, and malformations of the external
ear are present in approximately 36% (19).
Ultrasound scans of II.3, as well as of the mother
and unaffected sibling of the proband, II.7 and
III.2 respectively, were negative for abnormalities
of the urogenital system. The pregnancy was
terminated at 28 weeks of gestation and post-
mortem analysis indicated that the kidneys were
absent but that the ureters were present and blind
ending (Fig. 2b). The fetus also presented with
a rudimentary bladder, bilateral pre-auricular skin
tags and pulmonary hypoplasia. Based on the
available information, we hypothesized that this
was a case of familial BOR/BO syndrome and
elected to directly sequence the EYA1 gene for
mutational analysis.
Analysis revealed that II.3 and III.3 carried
a heterozygous mutation, EYA1 727G.T, which
altered the last coding nucleotide (nt) of exon 7
(Fig. 1a,b,c). Translation of this mutation (Fig. 1
c) would result in an in-frame stop codon instead
of a glutamic acid residue at amino acid position
243, and presumably truncate the protein and
ablate the EYAhr (Fig. 1a,b,c). We also detected
a novel SNP in intron 15 adjacent to the acceptor
site of exon 16 in this family (Fig. 1c). The
IVS15-3 C.T SNP as well as the causative
727G.T mutation were used to establish an
EYA1 haplotype map of this family (Fig. 3).
Both the mutation and the SNP were screened
against a panel of 155 and 165 random healthy
human controls, respectively. The 727G.T
mutation was not found in any individuals in
this panel; however, the IVS15-3 C.T SNP was
detected in seven individuals (4.2%). While
patient II.3 carries both the 727G.T mutation
and the SNP, it was determined that the IVS15-3
C.T SNP was not associated with a BOR/BO
syndrome phenotype as noted in other family
members (Fig. 3). We determined that not only
were the mutation and the SNP on separate
alleles but also that only the 727G.T mutation is
associated with the BOR/BO syndrome pheno-
type and is de novo to patient II.3 as neither of his
parents have the mutation (Fig. 3).
Due to the positions of the mutation and the
IVS15-3 C.T SNP, MaxENT scores were as-
sessed to determine if either alteration had an
effect on the strengths of the 5# and 3#ss (18). The
C.T variation of the SNP had negligible effect
on the recognition of the 3#ss of intron 15, with
MaxENT scores of 7.99 (CTGCAG) and 7.34
(CTGTAG). However, the G.T variation at nt
727 changed the MaxENT score of the 5#ss of
intron 7 from 8.55 (GCAGGT) to 1.05
(GCATGT), suggesting that the mutant tran-
script would have less likelihood for being
properly spliced. In this case, it is then expected
that the translation of exon 7 would likely
continue in frame into intron 7. When intron 7
Fig. 2. Variable familial phenotypes. (a) The right ear of II.3. The black arrowhead indicates a unilateral pre-auricular pit.
Additionally, this individual has hearing loss of an unknown etiology in this ear and an apparently overfolded superior helix.
(b) The urinary tract of the proband III.3 at 28 weeks of gestation. The kidneys are absent; however, the presence of the
ureters, the lengths of which are marked by the white bars, indicates that the metanephros was capable of inducing the ureteric
bud from the nephric duct. The approximate position of where the kidneys should be is noted by the white asterisks. Ad,
adrenal gland; b, bladder; u, ureter; ur, urethra.
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is in frame, the first stop codon is observed at
IVS7 1 138, and the first 1 kb of the intron
contains 22 stop codons.
Discussion
BOR/BO syndrome is an autosomal dominant
developmental disorder that features a wide
intrafamilial variability, variable penetrance and
a prevalence of 1:40,000 live births (2, 7). We
have characterized a novel mutation in exon 7 of
the EYA1 gene that leads to BOR/BO syndrome
in a South African Afrikaner kindred. We
conclude that the E243X mutation in this family
would result in a truncated protein product
lacking the critical EYAhr (Fig. 1a). Our find-
ings demonstrate that the causative EYA1
727G.T mutation results in both a BOR and
a BO syndrome phenotype in this pedigree. This
finding is consistent with other reports (3–6) and
is supportive of the hypothesis that the variable
BOR/BO syndrome phenotype is likely influ-
enced by other genetic modifiers.
The unique renal phenotype observed in III.3
indicates that the metanephric mesenchyme was
not maintained past the inductive stage and
subsequently had undergone a dysgenic process
either by apoptosis or by other mechanism.
A similar atypical phenotype has been reported
in a new model of Eya1-deficient mice by
Sajithlal et al. (13). Using offspring generated
from intercrosses between Eya1 heterozygous null
(Eya11/2) and Eya1 hypomorphic (Eya1bor/1)
mice, the authors were able to determine that
a minimum of 20% of normal Eya1 expression
is required to induce the metanephric mesen-
chyme, but is insufficient to maintain normal
branching of the ureteric bud. While the Eya11/2
mice with 48% functional Eya1 have a low in-
cidence of renal anomalies (10, 13), the compound
heterozygote mutants (Eya1 bor/2) with 20%
functional Eya1 presented with bilateral absence
of the kidneys 100% of the time (13). In humans,
individuals with BOR syndrome only present with
severe renal abnormalities in approximately 6% of
the cases (7). The rare occurrences and inconsis-
tency of severe renal abnormalities in humans with
BOR syndrome and Eya11/2 mice are suggestive
that other factors such as modifying genes may
play a role in the severity of the BOR/BO
syndrome phenotype, and perhaps as to the degree
that the urogenital system will be affected. We
expect that these modifying genes would have
a temporal and spatial relationship with the EYA1
expression pattern (e.g. metanephric mesenchyme)
and that they either may or may not directly
interact with EYA1.
We were unable to determine the exact function
of the 727G.T mutation. Translation of the
mutation does result in a termination codon at
this position. However, we have also demonstrated
that the same end result could also be obtained if
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Fig. 3. Complete pedigree of family JCA7. Family members with a branchio-oto-renal/branchiootic (BOR/BO) syndrome
phenotype are denoted by blackened symbols. Haplotypes of the EYA1 gene at nucleotide position 727 and IVS15-3 are
included for each individual available for analysis. Individual II.2 died at 9 months of age from unknown causes and
individual III.1 presented with bilaterally absent kidneys at birth. Samples from these individuals were unavailable for
analysis. Only family members with a BOR/BO syndrome phenotype who were available for analysis possessed the 727G.T
mutation. The IVS15-3 C.T single nucleotide polymorphism is detectable in all three generations in this pedigree beginning
with I.2, and it is not associated with a BOR/BO syndrome phenotype.
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translation were allowed to continue into intron 7.
Additionally, because of the variable phenotypes in
this family, it appears that there are other factors
involved. One possibility is that the IVS15-3 C.T
SNP could influence the expression of the opposite
allele as II.3 is seemingly unaffected by renal
anomalies. However, we are unable to confirm this,
and more comprehensive gene expression studies
would be required to assess these influences.
Mutations in EYA1 are only detectable in approx-
imately 40% of those with a BOR/BO syndrome
phenotype (16), and in some cases an affected
individual without a mutation in EYA1 was found
to have mutations in the transcription factor SIX1
– an EYA1-binding partner (20). The EYA-SIX-
PAX developmental network does not appear to
have a dogmatic hierarchy, and expression of any
one gene in this network is multifactorial (8).
Further characterization of this network, as well as
of the various BOR/BO syndrome phenotypes in
humans and mice, may provide information useful
to elucidating these additional influencing factors.
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